Liraglutide: Nursing Drug Guide, Pancreatitis & NCLEX Review
Liraglutide (Victoza) is a once-daily GLP-1 injection for type 2 diabetes—often combined with metformin, sulfonylureas, or insulin. The bedside priority is recognizing acute pancreatitis (persistent severe abdominal pain, with or without vomiting), preventing hypoglycemia when secretagogues or insulin are not dose-reduced, never sharing pens between patients, and counseling on the thyroid C-cell tumor boxed warning before the first dose.
Thyroid C-cell tumors: Liraglutide caused thyroid C-cell tumors in rats and mice; whether Victoza causes medullary thyroid carcinoma (MTC) in humans is unknown. Contraindicated with personal or family history of MTC or multiple endocrine neoplasia syndrome type 2 (MEN 2). Teach neck mass, dysphagia, dyspnea, or persistent hoarseness.
Acute pancreatitis: Has been observed with GLP-1 receptor agonists including Victoza—observe for persistent or severe abdominal pain (sometimes radiating to the back), with or without vomiting; discontinue if pancreatitis is suspected and do not restart if confirmed.
Hypoglycemia & pen sharing: Insulin secretagogues or insulin increase hypoglycemia risk when combined with Victoza—reduce those doses when starting liraglutide. Never share a Victoza pen between patients, even if the needle is changed.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every Victoza dose, screen for persistent severe abdominal pain suggestive of pancreatitis, check capillary glucose if on insulin or a sulfonylurea, confirm the pen delivers the ordered dose (0.6, 1.2, or 1.8 mg), and verify the pen is single-patient use only. Hold and notify the prescriber for pancreatitis symptoms, symptomatic hypoglycemia, or planned duplicate liraglutide-containing therapy (e.g., Saxenda).
Most common brand names
Liraglutide is the generic name for a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection. The primary U.S. brand for type 2 diabetes is Victoza. Saxenda is a separate higher-dose liraglutide product for chronic weight management—do not coadminister with Victoza or other liraglutide-containing products per labeling.
Victoza is supplied as a 6 mg/mL solution in a prefilled, single-patient-use pen delivering doses of 0.6 mg, 1.2 mg, or 1.8 mg. Do not confuse with weekly GLP-1 pens (e.g., dulaglutide) or with rapid-acting insulin pens stored in the same refrigerator.
Why we give it — Indications
Victoza (liraglutide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. Coadministration with other liraglutide-containing products is not recommended.
| Use | Detail |
|---|---|
| Type 2 diabetes — glycemic control | Once-daily subcutaneous injection with diet and exercise; may combine with metformin, sulfonylureas, or insulin glargine per prescriber plan |
| Cardiovascular risk reduction (adults) | Reduces risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (LEADER trial per labeling) |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Liraglutide activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, decreasing glucagon secretion, and slowing gastric emptying. Nurses see lower fasting and postprandial glucose and often modest weight loss—but also common nausea, vomiting, and delayed gastric emptying that can affect oral medication absorption. When insulin or sulfonylureas continue at pre-liraglutide doses, hypoglycemia risk rises per labeling.
Dosing overview
Verify pen dose selection (0.6, 1.2, or 1.8 mg) against current Victoza prescribing information. Titrate only per prescriber—adults increase from 0.6 mg to 1.2 mg after one week, then to 1.8 mg after at least one week on 1.2 mg if additional glycemic control is needed.
Missed dose: Resume at the next scheduled once-daily dose; do not take an extra dose or increase the dose to make up for a missed dose. If more than 3 days have elapsed since the last Victoza dose, reinitiate at 0.6 mg once daily and titrate per prescriber to reduce GI adverse reactions on reinitiation (Victoza labeling).
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (SC) | Tmax 8–12 hours after subcutaneous dose | Once-daily timing flexible; GI effects may precede full glycemic benefit |
| Half-life | ~13 hours (elimination half-life after SC administration) | Missed dose >3 days → reinitiate at 0.6 mg to limit GI symptoms on restart |
| Bioavailability | ~55% absolute bioavailability after subcutaneous administration | Rotate abdomen, thigh, or upper arm sites per labeling |
| Duration / steady state | Steady-state exposure reached with daily dosing | Trend HbA1c over months; monitor glucose when combined with insulin or secretagogues |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm type 2 diabetes indication—Victoza is not indicated for type 1 diabetes per labeling
- Screen personal/family history of medullary thyroid carcinoma (MTC) and MEN 2; review neck symptoms and prior GLP-1 hypersensitivity
- Reconcile insulin, sulfonylurea (e.g., glipizide), or basal insulin doses; complete medication reconciliation and hypoglycemia teaching before first injection; follow high-alert medication administration protocols when insulin is co-prescribed
Contraindications
- Personal or family history of MTC or MEN 2 (boxed warning)
- Serious hypersensitivity to liraglutide or product components (anaphylaxis or angioedema reported)
- Not recommended in severe gastrointestinal disease, including severe gastroparesis (not studied)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Insulin secretagogues / insulin | Increased hypoglycemia risk, including severe hypoglycemia (labeled warning) | Confirm reduced SU/insulin dose when liraglutide starts; teach hypoglycemia recognition; check capillary glucose per protocol |
| Oral medications (delayed gastric emptying) | Liraglutide slows gastric emptying; may impact absorption of oral drugs | Flag narrow-index oral drugs to pharmacy; monitor clinical effect when starting or escalating liraglutide |
| Other GLP-1 receptor agonists | Duplicate incretin therapy increases adverse effects without benefit | Hold duplicate orders; verify only one GLP-1 agonist on MAR |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Subcutaneous injection once daily via Victoza prefilled pen into abdomen, thigh, or upper arm at any time of day, with or without meals; rotate sites per labeling.
- Inspect solution before each injection—clear, colorless, and free of particles; do not use if cloudy or particulate
- When using with insulin, administer as separate injections—never mix; may use same body region but not adjacent sites
- Never share Victoza pens between patients, even if the needle is changed; use new needle per injection per labeling
- Refrigerate unused pens; do not freeze; follow Instructions for Use for in-use storage at room temperature
Confirm the pen is dialed to the ordered dose (0.6, 1.2, or 1.8 mg)—not Saxenda or another GLP-1 product. If the patient takes insulin or a sulfonylurea, assess for hypoglycemia before injection and ensure fast-acting carbohydrate is available.
Expected therapeutic response
- Lower fasting and postprandial glucose; downward trend in HbA1c over weeks to months
- Modest weight loss may occur—document baseline weight and ongoing trend
- Cardiovascular risk reduction in indicated adults is a long-term outcome—continue nursing surveillance for hypoglycemia and GI tolerance
Red flags — Stop and act
GLP-1 therapy can mask worsening glycemia when vomiting prevents intake, or unmask hypoglycemia when insulin doses are not reduced. Escalate early for abdominal pain and dehydration.
- Persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting—suspect pancreatitis; discontinue Victoza per labeling
- Glucose <54 mg/dL or severe hypoglycemia requiring assistance—treat immediately; review insulin/secretagogue doses
- Anaphylaxis, angioedema, or serious systemic hypersensitivity after injection
- Prolonged GI losses with oliguria or dizziness—suspect dehydration-related acute kidney injury; monitor intake and renal function
- New neck mass, dysphagia, dyspnea, or persistent hoarseness—thyroid tumor symptoms per boxed warning counseling
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Nausea, diarrhea, vomiting, decreased appetite, dyspepsia, constipation | Incidence ≥5% in clinical trials (labeling) | Small frequent meals, hydration teaching; hold and escalate if severe or persistent; monitor renal function with volume loss |
| Hypoglycemia (with insulin or secretagogue) | Increased risk when combined; severe hypoglycemia reported | Verify dose reductions of SU/insulin at initiation; teach recognition and 15–15 rule per protocol |
| Injection-site reactions | Reported; higher in pediatric patients than adults per labeling | Rotate sites; distinguish local reaction from cellulitis |
| Acute pancreatitis | Labeled warning; discontinue if suspected; do not restart if confirmed | Stop drug, notify prescriber, supportive care and serial assessment per protocol |
| Hypersensitivity (anaphylaxis, angioedema) | Postmarketing serious reactions | Discontinue permanently; emergency treatment per anaphylaxis protocol |
| Acute gallbladder disease, acute kidney injury, pulmonary aspiration with anesthesia | Labeled warnings | RUQ pain → gallbladder studies; GI losses → renal monitoring; instruct patients to inform providers of planned surgery or procedures |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Overdoses have been reported in Victoza clinical trials and post-marketing use. Observed effects have included severe nausea, severe vomiting, and severe hypoglycemia per labeling.
Overdose management
- Antidote: Not specified in the reviewed prescribing information—no specific reversal agent listed
- Initiate supportive treatment according to clinical signs and symptoms; monitor plasma glucose frequently
- Contact local poison control or toxicology services per facility protocol and local emergency guidance for additional direction
Look-alike / sound-alike and error prevention
- Victoza vs Saxenda—both contain liraglutide but different indications and dose ranges; coadministration is not recommended
- Victoza vs weekly GLP-1 pens—daily Victoza vs dulaglutide or semaglutide; verify drug name and schedule on MAR
- Victoza vs insulin pens—store and label separately in shared refrigerators; read product name on every pass
- Dose dial errors—0.6 mg vs 1.2 mg vs 1.8 mg; confirm selected dose on pen window before injecting
- Pen sharing—never use one Victoza pen for more than one patient, even with a new needle (labeled warning)
- Duplicate incretin therapy—do not administer two GLP-1 receptor agonists or two liraglutide products concurrently
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Not applicable—subcutaneous prefilled pen/syringe only |
| Food timing | Not applicable to route; no fasting requirement specified for SC injection |
| Storage | Refrigerate per product labeling; allow 15–30 minutes at room temperature before injection; protect from light/freezing per Instructions for Use |
| Site rotation | Alternate thigh and abdomen; avoid tender, bruised, red, or hard areas |
| Missed dose | Take at next scheduled daily dose—no extra dose; if >3 days since last dose, reinitiate 0.6 mg and retitrate |
| Commonly missed | Not reducing insulin/SU when Victoza starts; sharing pens between family members; confusing Victoza with Saxenda |
| Ask pharmacy when | Pen device change, renal impairment with severe GI symptoms, or overlapping GLP-1 orders |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults (≥65) on insulin or sulfonylureas | Higher hypoglycemia vulnerability—use lower glucose targets cautiously and teach family assistance with severe hypoglycemia |
| Renal impairment / ESRD | No dose adjustment, but monitor renal function with severe GI reactions; acute kidney injury reported with dehydration per labeling |
| History of diabetic retinopathy | Retinopathy complications reported more often in patients with prior retinopathy in CV outcomes trial—coordinate ophthalmology follow-up |
| Pregnancy | Victoza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus per labeling; coordinate MDT decision because poorly controlled diabetes also harms pregnancy outcomes. |
| Lactation | There are no data on the presence of liraglutide in human milk, effects on the breastfed infant, or effects on milk production per Victoza labeling. Consider developmental and health benefits of breastfeeding along with the mother’s clinical need for Victoza and potential adverse effects on the breastfed infant from Victoza or the underlying maternal condition. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Capillary blood glucose and blood glucose monitoring when combined with insulin or secretagogues—especially after dose changes
- HbA1c trend, weight, blood pressure, and basic metabolic panel (glucose, creatinine/eGFR, electrolytes) with persistent GI losses or suspected pancreatitis
- Abdominal pain pattern, hydration status, injection sites, and thyroid symptom screening per boxed warning counseling
Document
- Pen strength (mg), injection site, day of week, patient/caregiver education completion, and tolerance
- Hypoglycemia episodes, hold actions, prescriber/pharmacy notification for pancreatitis or hypersensitivity suspicion
- Co-administered diabetes medications and any insulin/SU dose reductions at initiation
Patient teaching
- Know hypoglycemia symptoms (shakiness, sweating, confusion)—keep fast-acting carbohydrate available if using insulin or a sulfonylurea
- Report persistent severe stomach pain, especially if radiating to the back, or ongoing vomiting—do not take the next dose until the prescriber advises
- Stay hydrated if nausea or diarrhea occur; seek care for signs of dehydration
- Rotate daily injection sites within abdomen, thigh, or upper arm; report neck lump, hoarseness, trouble swallowing, or breathing problems
- If a daily dose is missed, take the next scheduled dose—do not double. If more than 3 days pass without Victoza, contact the care team before restarting (usually reinitiate at 0.6 mg)
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Suspected acute pancreatitis (persistent severe abdominal pain, with or without vomiting)—hold and notify prescriber; discontinue if confirmed
- Symptomatic hypoglycemia until treated and insulin/secretagogue doses reviewed
- Serious hypersensitivity or anaphylaxis after any dose—do not rechallenge
- Personal/family history of MTC or MEN 2 not previously cleared—do not administer
- Wrong product (Victoza vs Saxenda), cloudy/particulate solution, expired pen, duplicate liraglutide-containing therapy, or pen previously used by another person
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Diabetes clinic and med-surg nurses often teach once-daily Victoza self-injection while insulin or sulfonylureas remain on the MAR. Build pancreatitis recognition, hypoglycemia prevention, and pen-sharing prohibition into every visit—not only the first pen training.
1. Check-before-you-give protocol
- Right patient, drug (Victoza/liraglutide), pen dose (0.6, 1.2, or 1.8 mg), route, and daily schedule
- Capillary glucose if on insulin or secretagogue; assess for nausea, vomiting, or abdominal pain
- Screen MTC/MEN 2 history and thyroid symptoms; confirm no duplicate GLP-1 on MAR
- Inspect pen solution, refrigeration status, site rotation, and patient/caregiver pen competency
2. High-alert and safety badge
Not a traditional high-alert medication, but carries a boxed warning and severe hypoglycemia risk with insulin/secretagoguesUse insulin-style safety rigor for glucose checks, dose-reduction verification, and pancreatitis holds even when patients self-administer at home.
3. Clinical workflow: hold and question rules
- If glucose is symptomatically low, treat hypoglycemia first, hold Victoza if vomiting prevents intake, and notify prescriber to review insulin/SU doses
- Persistent severe abdominal pain radiating to the back → hold Victoza, notify prescriber same day; discontinue if pancreatitis confirmed
- Wrong pen product, shared pen, or duplicate liraglutide therapy → hold and call pharmacy before injecting
4. Critical teach-back questions
- “What should you do if you miss your daily Victoza dose?” (Patient should take the next scheduled dose without doubling; if more than 3 days have passed, contact the prescriber—usually restart at 0.6 mg and retitrate.)
- “What symptoms mean you should stop the pen and call your care team?” (Patient should name severe stomach pain, ongoing vomiting, signs of low blood sugar, or neck lump/hoarseness.)
5. Care coordination
Prescriber / endocrinology: Titrate Victoza, adjust insulin/secretagogue doses at initiation, manage suspected pancreatitis and perioperative GLP-1 planning
Pharmacist: Pen device training, LASA checks with other GLP-1 or insulin products, renal monitoring with severe GI adverse reactions
🧠 Quick mental checklist
- Any persistent severe abdominal pain, vomiting, or pain radiating to the back since the last dose?
- Is the patient on insulin or a sulfonylurea—and was the dose reduced when Victoza started?
- Is this the patient’s own Victoza pen—never shared between people?
- Does the dialed dose (0.6, 1.2, or 1.8 mg) match the order?
- MTC/MEN 2 history cleared and thyroid symptoms reviewed?
Liraglutide NCLEX practice questions
Practice NCLEX-style clinical judgment practice for liraglutide using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, pancreatitis cue recognition (SATA), lipase trend interpretation, matrix urgency sorting, missed-dose judgment, and labeling cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Victoza (liraglutide) 1.8 mg subcutaneous once daily — due 0800 today; held for abdominal pain
- Metformin 1000 mg PO BID — held while NPO for workup
- Insulin glargine 18 units subcutaneous at bedtime — continue per prescriber if eating
- Started Victoza 0.6 mg daily 4 weeks ago; increased to 1.2 mg after 1 week, then 1.8 mg 3 days ago
- No other liraglutide-containing products on MAR
- Admission HbA1c 8.1%; BMP today: glucose 162 mg/dL, creatinine 1.1 mg/dL, eGFR 68 mL/min
- Lipase: 186 U/L (AM) → 412 U/L (noon); amylase 142 → 298 U/L
- Prior lipase on admission 78 U/L (within reference)
- 1100: HR 104; BP 132/78; RR 20; SpO2 97% on room air; temp 37.9 °C
- Epigastric pain 8/10, radiating to back; two episodes of vomiting since 0600
- Intake 200 mL oral fluids since midnight; urine output 120 mL (below baseline)
- 0630: Nausea since Victoza increased to 1.8 mg three days ago
- 0900: Patient reports severe constant epigastric pain; Victoza held; prescriber notified
- 1030: NPO except ice chips; IV fluids started; repeat lipase ordered
- Patient asks if roommate may borrow Victoza pen because pharmacy is closed
Answer key & rationale
Frequently asked questions
When should a nurse hold liraglutide and contact the prescriber?
Hold for suspected acute pancreatitis (persistent severe abdominal pain, with or without vomiting), confirmed pancreatitis, serious hypersensitivity, symptomatic hypoglycemia until treated, MTC/MEN 2 contraindications, wrong product or dose, shared pen use, or duplicate liraglutide-containing therapy. Victoza labeling directs discontinuation if pancreatitis is suspected and not restarting if confirmed.
Why does liraglutide increase hypoglycemia risk?
Concomitant insulin secretagogues or insulin increase hypoglycemia risk, including severe hypoglycemia, per Victoza labeling. Reduce sulfonylurea or insulin doses when initiating liraglutide and teach patients to recognize and treat low blood glucose.
What adverse effects are most common on liraglutide?
Clinical trials report nausea, diarrhea, vomiting, decreased appetite, dyspepsia, and constipation at incidence 5% or greater per labeling. Serious concerns include acute pancreatitis, hypersensitivity, acute kidney injury from volume depletion, acute gallbladder disease, and pulmonary aspiration with anesthesia or deep sedation.
What is the boxed warning for liraglutide?
Liraglutide caused thyroid C-cell tumors in rats; human relevance is unknown. Victoza is contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2. Counsel patients on neck mass, dysphagia, dyspnea, or persistent hoarseness.
Is there an antidote for liraglutide overdose?
Not specified in the reviewed prescribing information. Overdoses have been reported with severe nausea, severe vomiting, and severe hypoglycemia. Provide supportive treatment per clinical signs with frequent plasma glucose monitoring; contact local poison control or toxicology services per facility protocol.
How should nurses manage a missed daily Victoza dose?
Resume at the next scheduled once-daily dose; do not take an extra dose or double the dose. If more than 3 days have elapsed since the last Victoza dose, reinitiate at 0.6 mg once daily and titrate per prescriber to reduce GI adverse reactions on reinitiation.
References
-
U.S. National Library of Medicine. VICTOZA (liraglutide) injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
-
U.S. Food and Drug Administration. Victoza (liraglutide) prescribing information label PDF.https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022341s044lbl.pdf
-
Novo Nordisk. Victoza (liraglutide) U.S. prescribing information.https://www.novo-pi.com/victoza.pdf
-
American Diabetes Association. Standards of Care in Diabetes.https://diabetesjournals.org/care/issue/49/Supplement_1
-
Institute for Safe Medication Practices. ISMP List of High-Alert Medications in Acute Care Settings (insulin and hypoglycemic agents).https://www.ismp.org/recommendations/high-alert-medications-acute-list
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.